1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Godavari Drugs Limited

Godavari Drugs Limited

BBSE:GODAVARI
124.15
INR
+2.20
(+1.80%)
5.04EPS
23.68P/E
1.22BMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
12.53
72.83
94.44
100.28
85.48
110.61
127.23
162.84
214.08
212.09
208.14
150.62
140.5
134.68
Basic EPS, GAAP
2.06
4.84
1.79
2.4
1.1
1.6
2.66
5.48
6.97
5.03
7.37
5.82
5.43
5.09
Free Cash Flow per Basic Share
-0.06
-8.04
-8.77
0.39
0.26
1.5
-0.86
-0.46
7.95
5.16
6.92
-11.7
-34.51
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
12.63
17.34
19.14
21.54
22.64
24.24
26.9
32.38
39.35
44.38
51.74
57.56
74.85
- -
Tangible Book Value per Share
12.21
17.34
19.14
21.54
22.64
24.24
26.9
32.38
39.35
44.38
51.74
57.56
74.85
- -
Basic Weighted Avg Shares
8
8
8
8
8
8
8
8
8
8
8
8
8
8
Sales/Revenue/Turnover
94
548
711
756
644
835
957
1,227
1,611
1,596
1,567
1,134
1,058
1,100
Operating Margin (%)
9.47
9.88
5.47
5.9
4.77
5.27
5.14
7.02
6.11
6.21
7.32
8.55
8.06
6.83
Depreciation Expense
10
7
6
8
10
11
12
12
17
19
20
24
24
24
Net Income, GAAP
16
36
14
18
8
12
20
41
52
38
55
44
41
42
Effective Tax Rate (%)
- -
22.96
37.97
33.19
36.88
30.78
12.59
27.66
25.29
23.28
19.83
22.14
19.24
15.79
Profit Margin (%)
16.45
6.65
1.9
2.39
1.29
1.45
2.09
3.37
3.26
2.37
3.54
3.86
3.86
3.78
Working Capital
34
98
93
91
99
103
96
171
166
133
65
57
267
- -
LT Debt
24
36
39
44
66
80
112
145
118
119
112
239
370
- -
Total Equity
95
131
144
162
170
183
203
244
296
334
390
433
758
- -
Return on Invested Capital (%)
- -
23.51
9.38
9.61
5.67
7.9
9.68
11.96
13.37
10.68
9.62
7.32
5.36
- -
Return on Capital (%)
- -
24.71
9.42
9.64
5.12
7.02
8.4
11.05
12.09
8.34
9.16
7.19
5.22
- -
Return on Common Equity (%)
17.77
32.32
9.84
11.81
4.99
6.85
10.39
18.49
19.42
12.01
15.33
10.64
6.86
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
450
- -
LT Borrowings
- -
370
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
8
10
10
Market Capitalization
579
871
1,221

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
1,118
- -
Cash, Cash Equivalents & STI
- -
120
- -
Accounts Receivable, Net
- -
436
- -
Inventories
- -
461
- -
Total Current Liabilities
- -
851
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
450
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
19.31%
27.4%
74.87%
Free Cash Flow
-178.22%
-382.64%
195.26%
Net Income, GAAP
21.54%
3.62%
-6.64%
Sales/Revenue/Turnover
5.82%
-1.15%
-6.65%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
322
261
296
255
1,134
2026
238
266
222
332
1,058
2027
280
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
2.17
1.45
1.02
1.19
5.82
2026
1.38
1.33
1.01
1.71
5.43
2027
1.1
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Mukund Kakani
Full Time Employees
112
Sector
Health technology
Industry
Pharmaceuticals: major
Address
1-8-303/34, Mayfair Secunderabad TS India 500003
IPO Date
Mar 6, 1995
Website
godavaridrugs.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Godavari Drugs Limited manufactures active pharmaceutical ingredients, drug intermediates and fine chemicals for the global life science industry from its production facility in Nanded, Maharashtra; core products include Ciprofloxacin HCl USP/EP/BP/IP, Ciprofloxacin Base USP/EP/BP/IP, Ciprofloxacin Lactate IH, Ciprofloxacin Betaine IH, Mefenamic Acid USP/EP/BP/IP, Enrofloxacin USP/EP/BP/IP and Ethambutol HCl USP/BP/IP, with upcoming active pharmaceutical ingredients such as Carbamazepine and Oxcarbazepine, as well as intermediates including A D Lactone for Spironolactone and 6 Mercaptopurine for Azathioprine. The company, founded in 1987 and headquartered at Sardar Patel Road, Secunderabad, Telangana, provides contract manufacturing and loan license services to multinational clients including Dr. Reddy’s Laboratories for Ciprofloxacin and RPG Life Sciences for AD Lactone intermediate, focusing on antibiotic, anti-tuberculosis, anti-allergy, anti-HIV, nootropic, xanthine and anticonvulsant therapeutic segments with cGMP-compliant and WHO GMP-accredited operations. Godavari Drugs maintains active strategic tie-ups for manufacturing while pursuing expansions such as acquiring 17.5 acres of land in MIDC Krushnoor, Nanded District, for capacity enhancement and upgrading effluent treatment plant and reverse osmosis systems to support 105 cubic meters per day capacities.